A Phase 1 Study of Alpelisib (BYL719), an α- Specific PI3K Inhibitor, in Japanese Patients with Advanced Solid Tumors

Authors

Keywords

Journal

Volume -, Issue -, Pages -

Publisher

Wiley

Online

2018-12-27

DOI

10.1111/cas.13923

Explore over 38,000 international journals covering a vast array of academic fields.

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now